Terms: = Lung cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Treatment
184 results:
1. Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell lung cancer Patients: A Field Synopsis and Meta-Analysis.
Sito H; Sharzehan MAK; Islam MA; Tan SC
Br J Biomed Sci; 2024; 81():11835. PubMed ID: 38450253
[No Abstract] [Full Text] [Related]
2. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
Mahgoub TM; Jordan EJ; Mahdi AF; Oettl V; Huefner S; O'Donovan N; Crown J; Collins DM
Cancer Chemother Pharmacol; 2024 May; 93(5):427-437. PubMed ID: 38226983
[TBL] [Abstract] [Full Text] [Related]
4. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
[TBL] [Abstract] [Full Text] [Related]
5. I-CBP112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs.
Strachowska M; Gronkowska K; Sobczak M; Grodzicka M; Michlewska S; Kołacz K; Sarkar T; Korszun J; Ionov M; Robaszkiewicz A
Biomed Pharmacother; 2023 Dec; 168():115798. PubMed ID: 37913733
[TBL] [Abstract] [Full Text] [Related]
6. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
[TBL] [Abstract] [Full Text] [Related]
7. Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells.
Reis JSD; Santos MARDC; da Costa KM; Freire-de-Lima CG; Morrot A; Previato JO; Previato LM; da Fonseca LM; Freire-de-Lima L
Matrix Biol; 2023 Apr; 118():47-68. PubMed ID: 36882122
[TBL] [Abstract] [Full Text] [Related]
8. Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T; Sakaguchi C; Hirano K; Kobe H; Ishida M; Nakano T; Tachibana Y; Tamiya N; Shiotsu S; Takeda T; Yamada T; Yokoyama T; Tsuchiya M; Nagasaka Y
Thorac Cancer; 2023 Apr; 14(11):1004-1011. PubMed ID: 36866788
[TBL] [Abstract] [Full Text] [Related]
9. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell lung cancer.
Ikeuchi N; Igata F; Kinoshita E; Kawabata T; Tan I; Osaki Y; Otsuka R; On R; Ikeda T; Nakao A; Sasaki T; Aoyama T; Hirano R; Harada T; Ebi N; Fujita M; Inoue H
Anticancer Res; 2023 Feb; 43(2):713-724. PubMed ID: 36697078
[TBL] [Abstract] [Full Text] [Related]
10. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract] [Full Text] [Related]
12. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
Trummer A; Bethge A; Dickgreber N; Dittrich I; Golpon H; Hoffknecht P; Overbeck TR; Wesseler C; Reck M
Lung Cancer; 2022 Dec; 174():141-145. PubMed ID: 36402005
[TBL] [Abstract] [Full Text] [Related]
13. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
[TBL] [Abstract] [Full Text] [Related]
14. The Effect and Mechanism of Curcumin Combined with Carboplatin Chemotherapy Promoting on Apoptosis of lung cancer HCC827 Cells.
Huang L; He X; Zuo X
J Immunol Res; 2022; 2022():1932692. PubMed ID: 35979255
[TBL] [Abstract] [Full Text] [Related]
15. [A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].
Zhong J; Wang J
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):717-724. PubMed ID: 35880337
[TBL] [Abstract] [Full Text] [Related]
16. PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
Thirusangu P; Ray U; Sarkar Bhattacharya S; Oien DB; Jin L; Staub J; Kannan N; Molina JR; Shridhar V
Oncogene; 2022 Aug; 41(33):4003-4017. PubMed ID: 35804016
[TBL] [Abstract] [Full Text] [Related]
17. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F; Ramalingam SS; Owonikoko T; Earp HS; DeRyckere D; Graham DK
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35708914
[TBL] [Abstract] [Full Text] [Related]
18. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Heersche N; Veerman GDM; de With M; Bins S; Assaraf YG; Dingemans AC; van Schaik RHN; Mathijssen RHJ; Jansman FGA
Drug Resist Updat; 2022 May; 62():100832. PubMed ID: 35427871
[TBL] [Abstract] [Full Text] [Related]
19. Noninvasive Evaluation of Multidrug Resistance via Imaging of abcg2/bcrp Multidrug Transporter in lung cancer Xenograft Models.
Li C; Yang Q; Chen Z; Qiu Y; Du Y; Wang R; He Q; Yang J; Zhen H; Kang L
Mol Pharm; 2022 Oct; 19(10):3521-3529. PubMed ID: 35427142
[TBL] [Abstract] [Full Text] [Related]
20. Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and abcg2 in vitro and ex vivo.
Zhang Y; Vagiannis D; Budagaga Y; Sabet Z; Hanke I; Rozkoš T; Hofman J
Biochem Pharmacol; 2022 May; 199():115009. PubMed ID: 35314165
[TBL] [Abstract] [Full Text] [Related]
[Next]